AR095499A1 - ANTICUERPOS MONOCLONALES CONTRA ANTITROMBINA b - Google Patents
ANTICUERPOS MONOCLONALES CONTRA ANTITROMBINA bInfo
- Publication number
- AR095499A1 AR095499A1 ARP140101104A ARP140101104A AR095499A1 AR 095499 A1 AR095499 A1 AR 095499A1 AR P140101104 A ARP140101104 A AR P140101104A AR P140101104 A ARP140101104 A AR P140101104A AR 095499 A1 AR095499 A1 AR 095499A1
- Authority
- AR
- Argentina
- Prior art keywords
- seq
- amino acids
- sequence
- antibody comprises
- antibody
- Prior art date
Links
- 150000001413 amino acids Chemical class 0.000 abstract 6
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 abstract 3
- 101100112922 Candida albicans CDR3 gene Chemical group 0.000 abstract 2
- 102100035360 Cerebellar degeneration-related antigen 1 Human genes 0.000 abstract 2
- 102100035361 Cerebellar degeneration-related protein 2 Human genes 0.000 abstract 2
- 101000737793 Homo sapiens Cerebellar degeneration-related antigen 1 Proteins 0.000 abstract 2
- 101000737796 Homo sapiens Cerebellar degeneration-related protein 2 Proteins 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 1
- 239000004019 antithrombin Substances 0.000 abstract 1
- 230000015271 coagulation Effects 0.000 abstract 1
- 238000005345 coagulation Methods 0.000 abstract 1
- 230000007547 defect Effects 0.000 abstract 1
- 230000007812 deficiency Effects 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 230000002068 genetic effect Effects 0.000 abstract 1
- 229960002897 heparin Drugs 0.000 abstract 1
- 229920000669 heparin Polymers 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000014508 negative regulation of coagulation Effects 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/38—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against protease inhibitors of peptide structure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Endocrinology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361784590P | 2013-03-14 | 2013-03-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR095499A1 true AR095499A1 (es) | 2015-10-21 |
Family
ID=50680168
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP140101104A AR095499A1 (es) | 2013-03-14 | 2014-03-14 | ANTICUERPOS MONOCLONALES CONTRA ANTITROMBINA b |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US9593166B2 (enExample) |
| EP (1) | EP2970500A1 (enExample) |
| JP (1) | JP2016519081A (enExample) |
| KR (1) | KR20150127202A (enExample) |
| CN (1) | CN105229033B (enExample) |
| AR (1) | AR095499A1 (enExample) |
| AU (1) | AU2014236198A1 (enExample) |
| BR (1) | BR112015021399A2 (enExample) |
| CA (1) | CA2916421A1 (enExample) |
| HK (1) | HK1215261A1 (enExample) |
| MX (1) | MX2015012441A (enExample) |
| PE (1) | PE20160533A1 (enExample) |
| RU (1) | RU2015143696A (enExample) |
| SG (1) | SG11201506886TA (enExample) |
| TW (1) | TW201529602A (enExample) |
| UY (1) | UY35457A (enExample) |
| WO (1) | WO2014153195A1 (enExample) |
| ZA (1) | ZA201507628B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201529602A (zh) * | 2013-03-14 | 2015-08-01 | Bayer Healthcare Llc | 對抗抗凝血酶β之單株抗體 |
| WO2015176738A1 (en) * | 2014-05-19 | 2015-11-26 | Nokia Solutions And Networks Oy | Re-establishment procedure in dual connectivity networks |
| MY180297A (en) | 2015-06-24 | 2020-11-27 | Hoffmann La Roche | Anti-transferrin receptor antibodies with tailored affinity |
| MX2018003822A (es) | 2015-10-02 | 2018-06-22 | Hoffmann La Roche | Anticuerpos biespecificos contra el cd20 humano y el receptor de transferrina humano y metodos de uso. |
| AR106189A1 (es) | 2015-10-02 | 2017-12-20 | Hoffmann La Roche | ANTICUERPOS BIESPECÍFICOS CONTRA EL A-b HUMANO Y EL RECEPTOR DE TRANSFERRINA HUMANO Y MÉTODOS DE USO |
| JP2019516347A (ja) * | 2016-03-18 | 2019-06-20 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | 抗アンチトロンビン単一ドメイン抗体及びそれを含むポリペプチド |
Family Cites Families (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5578253A (en) | 1978-12-11 | 1980-06-12 | Teikoku Hormone Mfg Co Ltd | Immune measurement of hito antithrombin 3 |
| US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
| BE896543A (fr) | 1983-04-22 | 1983-08-16 | Wallone Region | Ensembles d'anticorps monoclonaux deriges contre les proteines humaines impliquees dans la coagulation et la fibrinolyse du sang |
| JPH0644876B2 (ja) | 1985-12-13 | 1994-06-15 | 株式会社ヤトロン | 抗トロンビン・アンチトロンビン３複合体モノクローナル抗体、及びその製造方法、並びにそれを用いるトロンビン・アンチトロンビン３複合体の免疫定量法、及びそれを用いるトロンビン・アンチトロンビン３複合体の精製方法 |
| JPH0266458A (ja) | 1988-09-01 | 1990-03-06 | Takara Shuzo Co Ltd | ビトロネクチン及びビトロネクチン‐トロンビン‐アンチトロンビン３複合体の測定方法 |
| US5530101A (en) * | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| AU628960B2 (en) | 1989-04-07 | 1992-09-24 | Teijin Limited | Method of immunologically assaying human thrombin- antithrombin III complex, assay reagent and kit therefor |
| US7084260B1 (en) | 1996-10-10 | 2006-08-01 | Genpharm International, Inc. | High affinity human antibodies and human antibodies against human antigens |
| US6255458B1 (en) | 1990-08-29 | 2001-07-03 | Genpharm International | High affinity human antibodies and human antibodies against digoxin |
| JPH0694713A (ja) | 1991-07-31 | 1994-04-08 | Masashi Funayama | アンチトロンビンｉｉｉ活性の測定方法とそれを用いたアンチトロンビンｉｉｉ活性の測定キット |
| JPH07238099A (ja) * | 1994-02-25 | 1995-09-12 | Dai Ichi Pure Chem Co Ltd | モノクローナル抗体及びこれを用いる免疫学的測定法 |
| FR2718849B1 (fr) | 1994-04-14 | 1996-06-14 | Pasteur Sanofi Diagnostics | Procédé d'immunodosage de l'antithrombine III activée par un glycosaminoglycane, anticorps monoclonaux correspondants et leur procédé d'obtention. |
| US5753445A (en) | 1994-04-26 | 1998-05-19 | The Mount Sinai Medical Center Of The City University Of New York | Test for the detection of anti-heparin antibodies |
| JP3841364B2 (ja) | 1994-10-18 | 2006-11-01 | 株式会社三菱化学ヤトロン | 抗ヒトビトロネクチン・トロンビン・アンチトロンビンｉｉｉ 複合体モノクローナル抗体、ハイブリドーマ及び免疫学的測定方法 |
| DK0912738T3 (da) | 1996-05-22 | 2008-11-17 | Viventia Biotech Inc | Antigen-bindende-fragmenter der specifikt detekterer cancerceller, nukleotider der koder fragmenterne og anvendelse deraf til profylakse og detektion af cancere |
| EP0912728A1 (en) | 1996-05-31 | 1999-05-06 | MediGene Aktiengesellschaft | Novel synthetic protein structural templates for the generation, screening and evolution of functional molecular surfaces |
| ATE381260T1 (de) | 1999-05-13 | 2008-01-15 | Gtc Biotherapeutics Inc | Transgene hergestellte antithrombin iii und deren mutanten |
| JP2001321167A (ja) | 2000-05-10 | 2001-11-20 | Cosmo Research Inst | モノクローナル抗体 |
| EP2281843B1 (en) | 2000-06-16 | 2016-10-12 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to BLyS |
| US7598055B2 (en) | 2000-06-28 | 2009-10-06 | Glycofi, Inc. | N-acetylglucosaminyltransferase III expression in lower eukaryotes |
| US7625756B2 (en) | 2000-06-28 | 2009-12-01 | GycoFi, Inc. | Expression of class 2 mannosidase and class III mannosidase in lower eukaryotic cells |
| JP2002316999A (ja) | 2001-04-17 | 2002-10-31 | Dai Ichi Pure Chem Co Ltd | モノクローナル抗体 |
| US20090226429A1 (en) | 2001-05-25 | 2009-09-10 | Human Genome Sciences, Inc. | Antibodies That Immunospecifically Bind to TRAIL Receptors |
| WO2003089575A2 (en) | 2002-04-15 | 2003-10-30 | Human Genome Sciences, Inc. | Antibodies that specifically bind to tl5 |
| EP1530629B1 (en) | 2002-05-31 | 2011-08-31 | The University of Utah Research Foundation | Variants of antithrombin iii |
| EP1382615A1 (en) | 2002-07-15 | 2004-01-21 | Xerion Pharmaceuticals AG | MCAM inhibitors |
| AU2003289716A1 (en) | 2002-09-12 | 2004-04-30 | Incyte Corporation | Molecules for diagnostics and therapeutics |
| RU2262109C2 (ru) | 2002-12-30 | 2005-10-10 | Институт биохимической физики им. Н.М. Эмануэля Российской академии наук | Способ определения концентрации антитромбина iii в плазме крови |
| EP1603949B9 (en) | 2003-03-14 | 2011-02-02 | Wyeth LLC | Antibodies against human il-21 receptor and uses therefor |
| EP1633316A4 (en) | 2003-05-06 | 2008-04-02 | Human Genome Sciences Inc | ANTIBODIES BINDING IMMUNOSIPICALLY TO TRAIL RECEPTORS |
| GB2404981A (en) | 2003-08-15 | 2005-02-16 | Univ Geneve | Diagnostic method for stroke |
| US7638606B2 (en) | 2003-11-07 | 2009-12-29 | Immunex Corporation | Antibodies that bind interleukin-4 receptor |
| US7271245B2 (en) | 2004-02-13 | 2007-09-18 | The Scripps Research Institute | Methods and compositions for inhibition of metastasis |
| AU2005271523B2 (en) | 2004-08-03 | 2011-09-15 | Dyax Corp. | hk1-binding proteins |
| JP4829609B2 (ja) | 2004-12-22 | 2011-12-07 | 独立行政法人科学技術振興機構 | ヒト抗体酵素およびその生産方法 |
| AU2006210660B2 (en) | 2005-02-01 | 2011-12-01 | Morphosys Ag | Libraries and methods for isolating antibodies |
| JP2010533684A (ja) | 2007-07-20 | 2010-10-28 | ユニベルシテ パリ サッド １１ | 血液凝固異常の治療又は予防のための変異アンチトロンビンの使用 |
| ES2628395T3 (es) | 2007-08-15 | 2017-08-02 | Bayer Pharma Aktiengesellschaft | Anticuerpo regulado por proteasa |
| WO2009073471A1 (en) | 2007-11-29 | 2009-06-11 | Talecris Biotherapeutics, Inc. | Recombinantly modified plasmin |
| ES2346618B1 (es) | 2008-08-14 | 2011-08-03 | Universidad De Murcia | Anticuerpo monoclonal anti antitrombina citrulinada humana y sus usos. |
| NO330078B1 (no) | 2008-09-22 | 2011-02-14 | Optipro As | Fremgangsmåte og apparat for å overvåke slitasje i sikteduker |
| US20110311550A1 (en) | 2008-10-24 | 2011-12-22 | The Scripps Research Institute | Agents for hcv treatment |
| TWI513466B (zh) | 2010-01-20 | 2015-12-21 | Boehringer Ingelheim Int | 抗凝血劑解毒劑 |
| EP3401333B1 (en) | 2010-09-09 | 2021-05-19 | Purdue Research Foundation | Anti-human folate receptor beta antibodies and methods of use |
| US20140356377A1 (en) * | 2011-08-25 | 2014-12-04 | Umc Utrecht Holding B.V. | Compounds for use in boosting coagulation |
| JP6095678B2 (ja) | 2011-11-11 | 2017-03-15 | エスアイオーツー・メディカル・プロダクツ・インコーポレイテッド | 薬剤パッケージ用の不動態化、ｐＨ保護又は滑性皮膜、被覆プロセス及び装置 |
| TW201529602A (zh) * | 2013-03-14 | 2015-08-01 | Bayer Healthcare Llc | 對抗抗凝血酶β之單株抗體 |
| JP6094713B1 (ja) | 2016-06-30 | 2017-03-15 | 富士ゼロックス株式会社 | 定着部材、定着装置、及び画像形成装置 |
-
2014
- 2014-03-14 TW TW103109449A patent/TW201529602A/zh unknown
- 2014-03-14 KR KR1020157028131A patent/KR20150127202A/ko not_active Withdrawn
- 2014-03-14 CA CA2916421A patent/CA2916421A1/en not_active Abandoned
- 2014-03-14 UY UY0001035457A patent/UY35457A/es not_active Application Discontinuation
- 2014-03-14 BR BR112015021399A patent/BR112015021399A2/pt not_active IP Right Cessation
- 2014-03-14 US US14/214,382 patent/US9593166B2/en not_active Expired - Fee Related
- 2014-03-14 US US14/214,267 patent/US20140271660A1/en not_active Abandoned
- 2014-03-14 US US14/770,222 patent/US9908942B2/en not_active Expired - Fee Related
- 2014-03-14 HK HK16103100.3A patent/HK1215261A1/zh unknown
- 2014-03-14 SG SG11201506886TA patent/SG11201506886TA/en unknown
- 2014-03-14 EP EP14722465.3A patent/EP2970500A1/en not_active Withdrawn
- 2014-03-14 RU RU2015143696A patent/RU2015143696A/ru not_active Application Discontinuation
- 2014-03-14 PE PE2015001972A patent/PE20160533A1/es not_active Application Discontinuation
- 2014-03-14 JP JP2016503128A patent/JP2016519081A/ja active Pending
- 2014-03-14 MX MX2015012441A patent/MX2015012441A/es unknown
- 2014-03-14 AR ARP140101104A patent/AR095499A1/es unknown
- 2014-03-14 AU AU2014236198A patent/AU2014236198A1/en not_active Abandoned
- 2014-03-14 CN CN201480028085.2A patent/CN105229033B/zh not_active Expired - Fee Related
- 2014-03-14 WO PCT/US2014/029541 patent/WO2014153195A1/en not_active Ceased
-
2015
- 2015-10-13 ZA ZA2015/07628A patent/ZA201507628B/en unknown
-
2018
- 2018-02-28 US US15/908,705 patent/US10144784B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| AU2014236198A1 (en) | 2015-10-15 |
| US20180244799A1 (en) | 2018-08-30 |
| JP2016519081A (ja) | 2016-06-30 |
| ZA201507628B (en) | 2017-11-29 |
| SG11201506886TA (en) | 2015-09-29 |
| BR112015021399A2 (pt) | 2017-07-18 |
| WO2014153195A1 (en) | 2014-09-25 |
| KR20150127202A (ko) | 2015-11-16 |
| US20140271660A1 (en) | 2014-09-18 |
| UY35457A (es) | 2014-10-31 |
| US20160024222A1 (en) | 2016-01-28 |
| CN105229033B (zh) | 2019-04-23 |
| CN105229033A (zh) | 2016-01-06 |
| CA2916421A1 (en) | 2014-09-25 |
| EP2970500A1 (en) | 2016-01-20 |
| RU2015143696A (ru) | 2017-04-19 |
| HK1215261A1 (zh) | 2016-08-19 |
| US9908942B2 (en) | 2018-03-06 |
| PE20160533A1 (es) | 2016-06-09 |
| US9593166B2 (en) | 2017-03-14 |
| MX2015012441A (es) | 2016-08-08 |
| US20140271661A1 (en) | 2014-09-18 |
| US10144784B2 (en) | 2018-12-04 |
| TW201529602A (zh) | 2015-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR103868A1 (es) | Anticuerpos anti-cd47 como agentes terapéuticos | |
| AR104213A1 (es) | Anticuerpos anti-cd38 como agentes terapéuticos | |
| AR105313A1 (es) | Anticuerpo anti-cd137 terapéutico | |
| AR111630A1 (es) | ANTICUERPOS ANTI-SIRPa | |
| FI3389699T3 (fi) | Kimeerisiä ja humanisoituja humaaneja monoklonaalisia ctla4-vasta-aineita ja niiden käyttötapoja | |
| AR093803A1 (es) | Composiciones y metodos de anticuerpos de marcaje de epo | |
| PE20241623A1 (es) | Optimizacion de anticuerpos que se fijan al gen de activacion de linfocitos 3 (lag-3) y usos de los mismos | |
| BR112019008010A2 (pt) | anticorpo monoclonal isolado ou fragmento imunologicamente ativo do mesmo, anticorpo monoclonal biespecífico isolado, composição farmacêutica, método para tratamento de uma doença em um sujeito humano em necessidade do mesmo, proteína de fusão, epítopo imunodominante codificado pelo gene cd47, e, molécula biológica | |
| AR106752A1 (es) | Proteínas de unión a pd1 / ctla4 | |
| AR110017A1 (es) | Anticuerpos de pd-1 y usos de estos | |
| PE20240913A1 (es) | Anticuerpos anti-il-2r agonistas y metodos de uso | |
| AR099698A1 (es) | Anticuerpos contra el c5 que tienen farmacocinética mejorada | |
| AR106184A1 (es) | Proteínas de unión a pd-1 y sus métodos de uso | |
| AR072897A1 (es) | Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5 | |
| UA116194C2 (uk) | Антитіло, яке специфічно зв'язується з людським альфа-синуклеїном | |
| CL2018003608A1 (es) | Anticuerpo aislado o fragmento de unión a antígeno del mismo que se une específicamente interleucina-25 hjumana (il-2525); composición farmacéutica que lo comprende; uso de dicha composición farmacéutica para tratar una enfermedad o trastorno asociado con la actividad o expresión de il-25. (divisional solicitud 201700703) | |
| AR109882A1 (es) | Anticuerpos monoclonales neutralizantes anti-tl1a | |
| PE20221580A1 (es) | Anticuerpos terapeuticos y sus usos | |
| AR104280A1 (es) | Terapia de combinación con factores de coagulación y anticuerpos multiespecíficos | |
| EA202091590A1 (ru) | Антитела против pd-l1 и варианты их применения | |
| AR095499A1 (es) | ANTICUERPOS MONOCLONALES CONTRA ANTITROMBINA b | |
| AR085955A1 (es) | Proteinas de union al antigeno | |
| SI2542257T1 (en) | Optimized monoclonal antibodies against Tissue Factor Pathway Inhibitor (TFPI) | |
| CY1121538T1 (el) | Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi) | |
| AR087567A1 (es) | Anticuerpos anti-tie2 y usos de los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |